Lukas Biomedical (ROCO:6814) FCF Margin % : -4.22% (As of Jun. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Lukas Biomedical FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Lukas Biomedical's Free Cash Flow for the six months ended in Jun. 2023 was NT$-4.8 Mil. Lukas Biomedical's Revenue for the six months ended in Jun. 2023 was NT$114.3 Mil. Therefore, Lukas Biomedical's FCF Margin % for the quarter that ended in Jun. 2023 was -4.22%.

As of today, Lukas Biomedical's current FCF Yield % is -0.53%.

The historical rank and industry rank for Lukas Biomedical's FCF Margin % or its related term are showing as below:

ROCO:6814' s FCF Margin % Range Over the Past 10 Years
Min: -16.61 Med: -3.64 Max: 11.05
Current: -2.75

During the past 5 years, the highest FCF Margin % of Lukas Biomedical was 11.05%. The lowest was -16.61%. And the median was -3.64%.

ROCO:6814's FCF Margin % is ranked better than
77.37% of 1043 companies
in the Biotechnology industry
Industry Median: -139.31 vs ROCO:6814: -2.75

Lukas Biomedical FCF Margin % Historical Data

The historical data trend for Lukas Biomedical's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lukas Biomedical FCF Margin % Chart

Lukas Biomedical Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

FCF Margin %

-3.64

-3.15

11.05

-16.61

-5.63

Lukas Biomedical Semi-Annual Data
	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
FCF Margin %	Get a 7-Day Free Trial					-18.15	-15.11	-10.79	-1.03	-4.22

Competitive Comparison of Lukas Biomedical's FCF Margin %

For the Biotechnology subindustry, Lukas Biomedical's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Lukas Biomedical's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lukas Biomedical's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Lukas Biomedical's FCF Margin % falls into.

Lukas Biomedical FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Lukas Biomedical's FCF Margin for the fiscal year that ended in Dec. 2022 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2022 )	/	Revenue (A: Dec. 2022 )
	=	-10.412	/	184.787
	=	-5.63 %

Lukas Biomedical's FCF Margin for the quarter that ended in Jun. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Jun. 2023 )	/	Revenue (Q: Jun. 2023 )
	=	-4.817	/	114.273
	=	-4.22 %

Lukas Biomedical FCF Margin % Related Terms

Thank you for viewing the detailed overview of Lukas Biomedical's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Lukas Biomedical (ROCO:6814) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lukas Biomedical Inc (ROCO:6814) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

Xinyi Road, Da'an District, 3rd Floor, No. 2, Lane 265, Section 4, Taipei, TWN

Website

https://www.lukas-bio.com.tw

Lukas Biomedical Inc is engaged in the research and development of immunotherapy for cancer treatment technologies. It researches on the Memory T cell (LuLym-T) to improve the clinical outcome of cancer treatment.

Lukas Biomedical (ROCO:6814) Headlines

No Headlines